Inflammatory Conditions - Zymfentra Prior Authorization Policy
Prior authorization policy for Zymfentra (infliximab-dyyb subcutaneous injection) covering FDA-approved indications Crohn's disease and ulcerative colitis in adults, specifying initial and continuation criteria, prescriber requirements, approval durations, and situations not recommended for approval including concurrent use with other biologics or targeted synthetic oral small molecule drugs.
Selected revision 02/11/2026 (history entry) after prior selected revisions and annual reviews.
Annual Revision 12/17/2025: Appendix: Otezla XR (apremilast-extended release tablets) was added.
Selected Revision 07/23/2025: Ulcerative Colitis initial therapy options removed previously.
Selected Revision 02/11/2026: Most recent selected revision date listed in header.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.